During the past decade, Xenoscience conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 20 clinical trials were completed, i.e. on average, 64.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Xenoscience" #1 sponsor was "Eli Lilly and Company" with 14 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "TauRx Therapeutics Ltd" with 4 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Eisai Inc." with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Xenoscience" #1 collaborator was "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "ClinEdge, LLC" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Xenoscience" are "Alzheimer's Disease" (14 trials), "Alzheimer Disease" (6 trials), "Migraine" (5 trials), "Multiple Sclerosis" (3 trials) and "Parkinson's Disease" (3 trials). Many other conditions were trialed in "Xenoscience" in a lesser frequency.

Most popular intervention types in "Xenoscience" are "Drug" (49 trials), "Other" (5 trials), "Biological" (3 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (26 trials), "Galcanezumab" (6 trials), "Lasmiditan" (3 trials), "Ocrelizumab" (3 trials) and "Antihistamine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Xenoscience" are 54 trials for "All" genders.

Currently, there are NaN active trials in "Xenoscience". undefined are not yet recruiting, 10 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Xenoscience, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Xenoscience, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".